Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.39 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.39 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.39 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.39 |
| ▸ | OXTR | P30559 | 1/20 | 0.39 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7946379 | 0.96 | CYP11B2 (0.42) | MKNK1MKNK2CYP11B2CSNK1DCSNK1E | |
| SCHEMBL7954864 | 0.89 | CYP11B2 (0.42) | CYP11B2AVPR2OXTRAVPR1AMEN1 | |
| SCHEMBL7946402 | 0.89 | KMT2A (0.43) | MKNK1MKNK2CYP11B2AVPR2OXTR | |
| SCHEMBL7954909 | 0.87 | MKNK1 (0.41) | MKNK1MKNK2CYP11B2CSNK1DCSNK1E | |
| SCHEMBL7960330 | 0.86 | MKNK1 (0.40) | MKNK1MKNK2CYP11B2CSNK1DCSNK1E | |
| SCHEMBL7953701 | 0.86 | CYP11B2 (0.42) | MKNK1MKNK2CYP11B2CSNK1DCSNK1E | |
| SCHEMBL7957167 | 0.86 | MKNK1 (0.40) | MKNK1MKNK2CYP11B2CSNK1DCSNK1E | |
| SCHEMBL7955055 | 0.85 | KMT2A (0.55) | CYP11B2MEN1KMT2AP2RX7ALDH1A1 | |
| SCHEMBL7954819 | 0.85 | KDM4E (0.42) | MKNK1MKNK2CYP11B2CSNK1DCSNK1E | |
| SCHEMBL2157432 | 0.84 | CYP11B2 (0.44) | MKNK1MKNK2CYP11B2CSNK1DCSNK1E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160346287-A1 | METHOD OF TREATING VIRAL INFECTIONS | EPIPHANY BIOSCIENCES, INC. | 2016-12-01 | — | — | US | claimed |
| US-20150050241-A1 | METHOD OF TREATING VIRAL INFECTIONS | EPIPHANY BIOSCIENCES, INC. | 2015-02-19 | — | — | US | claimed |
| WO-2014047562-A2 | METHOD OF TREATING AND/OR PREVENTING SHINGLES AND METHOD OF TREATING AND/OR PREVENTING ZOSTER ASSOCIATED PAIN | EPIPHANY BIOSCIENCES (US) | 2014-03-27 | — | — | WO | claimed |
| US-6194426-B1 | CONTROLLING TUMOR NECROSIS FACTOR | RHONA-POULENC RORER S.A. (FR) | 2001-02-27 | — | — | US | claimed |
| US-20250339502-A1 | RIBONUCLEASES FOR TREATING VIRAL INFECTIONS | ORGENESIS INC. (US) | 2025-11-06 | — | — | US | disclosed |
| WO-2024226832-A1 | RIBONUCLEASES FOR TREATING VIRAL INFECTIONS | ORGENESIS INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| CN-115976274-B | Composition, kit, method and application for detecting lichen planus pathogenesis inducement | 圣湘生物科技股份有限公司 | 2024-08-09 | — | — | CN | disclosed |
| US-20230147602-A1 | RIBONUCLEASES FOR TREATING VIRAL INFECTIONS | ORGENESIS INC. (US) | 2023-05-11 | — | — | US | disclosed |
| CN-115976274-A | Composition, kit, method and application for detecting pathogenesis cause of lichen planus | 圣湘生物科技股份有限公司 | 2023-04-18 | — | — | CN | disclosed |
| WO-2021188974-A1 | RIBONUCLEASES FOR TREATING VIRAL INFECTIONS | ORGENESIS INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| WO-2021188866-A1 | RIBONUCLEASES FOR TREATING VIRAL INFECTIONS | ORGENESIS INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| US-20210186977-A1 | MEDICAL USES | XNK Therapeutics AB (SE) | 2021-06-24 | — | — | US | disclosed |
| US-20110184011-A1 | Compounds | SELCIA LIMITED (GB) | 2011-07-28 | — | — | US | disclosed |
| EP-2274042-A1 | TREATMENT AND/OR PREVENTION OF MULTIPLE SCLEROSIS | Epiphany Biosciences, Inc. (US) | 2011-01-19 | — | — | EP | disclosed |
| WO-2010056053-A2 | METHOD FOR PREDICTING ACTIVATION ENERGY USING AN ATOMIC FINGERPRINT DESCRIPTOR OR AN ATOMIC DESCRIPTOR | 사단법인 분자설계연구소 (KR) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010029364-A1 | COMPOUNDS | SELCIA LIMITED (GB) | 2010-03-18 | — | — | WO | disclosed |
| WO-2009126327-A1 | TREATMENT AND/OR PREVENTION OF MULTIPLE SCLEROSIS | EPIPHANY BIOSCIENCES, INC. (US) | 2009-10-15 | — | — | WO | disclosed |
| US-6194426-B1 | CONTROLLING TUMOR NECROSIS FACTOR | RHONA-POULENC RORER S.A. (FR) | 2001-02-27 | — | — | US | disclosed |
| EP-0833635-A1 | NOVEL USE FOR PYRROLE DERIVATIVES | Aventis Pharma S.A. (FR) | 1998-04-08 | — | — | EP | disclosed |
| WO-1997000073-A1 | NOVEL USE FOR PYRROLE DERIVATIVES | RHONE-POULENC RORER S.A. (FR) | 1997-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160346287-A1 | METHOD OF TREATING VIRAL INFECTIONS | IFNG, BCL9, GDA | MKNK1 4580/4885MKNK2 4731/4885CYP11B2 148/4885 |
| US-20150050241-A1 | METHOD OF TREATING VIRAL INFECTIONS | IFNG, BCL9, GDA | MKNK1 4580/4885MKNK2 4731/4885CYP11B2 148/4885 |
| US-20110184011-A1 | Compounds | COL1A1, ALDH1A2, COL2A1 | MKNK1 3856/4885MKNK2 3481/4885CYP11B2 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.